Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of GNKG168 Administered by Intravenous Infusion in Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL)

NCT01035216 is registered in ClinicalTrials.gov with SBI Biotech Co., Ltd. as lead sponsor.

NCT NCT01035216
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01035216 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of GNKG168 Administered by Intravenous Infusion in Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL)
Lead sponsor
SBI Biotech Co., Ltd.
Phase
Phase 1
Overall status
Terminated
Start date
September 30, 2009
Completion date
November 30, 2013
Enrollment
18 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia